Which comes first? new study aims to optimize AML treatment sequence
NCT ID NCT05401097
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase II trial is for older adults with a specific type of acute myeloid leukemia (AML) that has IDH gene mutations. Researchers want to find out whether starting treatment with an IDH-targeted drug (ivosidenib or enasidenib) followed by standard therapy (azacitidine plus venetoclax) works better than the reverse order. About 125 participants who cannot have intensive chemotherapy will be randomly assigned to one of the two sequences. The goal is to see which order leads to better disease control and survival.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ivosidenib, enasidenib, azacitidine, venetoclax
What this could lead to
If successful, this study could identify the best sequence of targeted drugs and standard therapy to improve outcomes for older AML patients with IDH mutations.
What could go wrong
This is a phase II trial with only 125 participants, so results may not apply broadly. The study compares treatment order, not a new drug, so benefits may be modest.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Ohio State University Comprehensive Cancer Center
RECRUITINGColumbus, Ohio, 43210, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
UNC Hospitals, University of North Carolina at Chapel Hill
RECRUITINGChapel Hill, North Carolina, 27514, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
UT Southwestern Medical Center at Dallas
RECRUITINGDallas, Texas, 75235, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
University of Colorado
RECRUITINGAurora, Colorado, 80205, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact